0HFQ
vs
S&P 500
0HFQ
S&P 500
Over the past 12 months, 0HFQ has significantly outperformed S&P 500, delivering a return of +62% compared to S&P 500's +28% growth.
Stocks Performance
0HFQ vs S&P 500
Performance Gap
0HFQ vs S&P 500
Performance By Year
0HFQ vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
AnaptysBio Inc
Glance View
AnaptysBio is a biotechnology company that develops antibody-based medicines for immune and inflammatory diseases. It spends its time finding and testing antibodies that can turn down harmful immune activity in conditions such as autoimmune disorders. Its work is aimed at doctors and patients who need new treatment options, and its drugs are still in the development and approval process rather than sold like ordinary medicines. The company makes money in two main ways. It can earn payments from partners that use its antibody discovery work, including upfront fees, milestone payments, and royalties if partnered drugs succeed. It can also make money later from selling its own approved medicines, if any of its internal drug candidates reach the market. What makes AnaptysBio different is that it is both a drug developer and a discovery partner. Instead of relying only on one commercial product, it builds a pipeline of immune-focused antibody programs and also licenses some of its science to larger drug companies. That gives it a business model tied to both long-term drug development and outside collaboration deals.
